Treadwell Therapeutics Revenue and Competitors

Location

$118M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Treadwell Therapeutics's estimated annual revenue is currently $4.3M per year.(i)
  • Treadwell Therapeutics's estimated revenue per employee is $77,500
  • Treadwell Therapeutics's total funding is $118M.

Employee Data

  • Treadwell Therapeutics has 56 Employees.(i)
  • Treadwell Therapeutics grew their employee count by -8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M7250%N/AN/A
#2
$5.9M3815%N/AN/A
#3
$34.7M2246%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.9M6-14%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$4.2M27-16%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/

keywords:N/A

$118M

Total Funding

56

Number of Employees

$4.3M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Treadwell Therapeutics News

2022-04-19 - Treadwell Therapeutics Announces Fast Track Designation ...

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia...

2022-04-13 - Treadwell Therapeutics Announces the Appointment of JD ...

NEW YORK and HONG KONG, April 19, 2022 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company...

2022-03-30 - Treadwell Therapeutics and University Health Network Sign ...

Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.3M56-19%N/A
#2
$16.3M56-3%N/A
#3
$11.1M568%N/A
#4
$11.1M56-18%$283M
#5
$7.8M56-11%$108.8M